FlandersBio on Twitter

Follow us on Twitter

Life sciences database

Databank life sciences

in het nederlands in english

FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.

FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.

Amakem Therapeutics

Website: http://www.amakem.com
Email:
Phone: +32 11 28 69 82
FlandersBio Member
More address details

Business Focus

Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. The Company's lead candidate, AMA0076, targets glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness.

Amakem's product pipeline is based on its unique 'Localized Drug Action' platform which generates novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

Tags

Company Profile

Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem’s product pipeline is based on its unique ‘Localized Drug Action’ platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

Amakem’s lead candidate, AMA0076, is a novel, highly potent Rho Kinase (ROCK) inhibitor targeted at the treatment of glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness. AMA0076 has been shown in a number of in vivo models to be highly effective in reducing intraocular pressure (IOP), a major factor in glaucoma, while avoiding hyperemia. Also known as ‘red eye’, hyperemia results from excess blood flow in vessels in the white of the eye. It is a distressing and dose limiting side effect for patients that has hindered the progress of many otherwise promising glaucoma drugs.

Amakem is working to apply the ‘Localized Drug Action’ platform to a range of other eye diseases and has also demonstrated proof-of-concept for the technology in COPD (Chronic Obstructive Pulmonary Disease) and asthma.

Amakem is based in Belgium and located in the life sciences incubator “BioVille” at the University of Hasselt.

Science & Technology or Services

Amakem was founded to continue the development of its unique, locally acting kinase inhibitor concept (localized drug action) that the founders embarked upon during their Devgen tenure.

Product description

Amakem is developing locally acting small molecule drugs for major chronic diseases such as glaucoma, allergic asthma and chronic obstructive pulmonary disease (COPD). The company’s focus is on ROCK inhibitors for their smooth muscle relaxation and anti-inflammatory effects. Our pipeline, as well as information about the proprietary platform underlying the locally active kinase inhibitors can be discussed under confidentiality.

More info

Address: BioVille
Agoralaan Building A-bis
3590 Diepenbeek
Belgium

Route: Via Google Maps
Website: http://www.amakem.com

Phone: +32 11 28 69 82
Fax: +32 11 49 02 09
Foundation date: 1/2010
Email: info@amakem.com

Become a Member

Listen to some testimonials from companies that are a member of FlandersBio and discover the benefits of membership

Read more

Z Life Sciences

Looking behind the scenes of the vibrant life sciences sector in Flanders!

YouTube

Biotechstockmarket

Belgian biotech on Euronext

Belgian biotech on Euronext

FlandersBio Members

Biocartis SynteractHCR Merck Millipore Qualinmeds Rescop Pivot Park Cartagenia, a part of Agilent Technologies UgenTec Hugin Mugin research VIB Emtex IDDI Altran Odyscience ProDigest Adagio Company Belgian Coordinated Collections of Micro-organisms Essensys CMAST NXT-Dx bioskills icoMetrix Right Away Pepric Peira Antwerp University Hospital Medicim STERIS - division LIfesciences Air Consult Engineering Genticel

View all members

Life Sciences Map

Life Sciences Map

View Life Sciences Map

Back to top

Print